Free Trial

Weiss Ratings Reiterates "Sell (D)" Rating for DocGo (NASDAQ:DCGO)

DocGo logo with Medical background

Key Points

  • Weiss Ratings has maintained a "Sell (D)" rating for DocGo (NASDAQ:DCGO), with Zacks Research recently downgrading their stance from "Hold" to "Strong Sell."
  • DocGo reported a quarterly revenue of $80.42 million, exceeding analyst expectations, but missed earnings per share estimates at ($0.11).
  • The stock's current average price target is $3.24, while it has experienced a 1-year price range between $1.12 and $5.68.
  • Interested in DocGo? Here are five stocks we like better.

DocGo (NASDAQ:DCGO - Get Free Report)'s stock had its "sell (d)" rating reissued by equities researchers at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports.

DCGO has been the subject of several other reports. Zacks Research cut DocGo from a "hold" rating to a "strong sell" rating in a research report on Tuesday, October 7th. Canaccord Genuity Group boosted their price target on DocGo from $1.45 to $1.60 and gave the stock a "hold" rating in a research report on Thursday, August 21st. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $3.24.

Read Our Latest Analysis on DCGO

DocGo Price Performance

Shares of DCGO stock opened at $1.18 on Friday. The company has a market cap of $115.42 million, a price-to-earnings ratio of -6.21 and a beta of 0.95. The stock has a 50 day simple moving average of $1.44 and a 200-day simple moving average of $1.61. DocGo has a 1-year low of $1.12 and a 1-year high of $5.68.

DocGo (NASDAQ:DCGO - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.05). The business had revenue of $80.42 million for the quarter, compared to analyst estimates of $77.58 million. DocGo had a negative return on equity of 3.26% and a negative net margin of 4.20%. DocGo has set its FY 2025 guidance at EPS. Analysts anticipate that DocGo will post 0.25 earnings per share for the current fiscal year.

Institutional Trading of DocGo

Several large investors have recently made changes to their positions in the company. Summit Securities Group LLC purchased a new stake in DocGo in the 1st quarter valued at $34,000. CWM LLC grew its holdings in DocGo by 2,613.3% in the 2nd quarter. CWM LLC now owns 21,978 shares of the company's stock valued at $35,000 after buying an additional 21,168 shares in the last quarter. Cerity Partners LLC purchased a new stake in DocGo in the 2nd quarter valued at $37,000. Engineers Gate Manager LP purchased a new stake in DocGo in the 2nd quarter valued at $52,000. Finally, Strs Ohio purchased a new stake in DocGo in the 1st quarter valued at $76,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

About DocGo

(Get Free Report)

DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.

See Also

Analyst Recommendations for DocGo (NASDAQ:DCGO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in DocGo Right Now?

Before you consider DocGo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DocGo wasn't on the list.

While DocGo currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.